Description: Bonesupport Holding AB (publ), an orthobiologics company, develops and commercializes injectable bio-ceramic bone graft substitutes in Europe, North America, and internationally. The company provides CERAMENT Bone Void Filler, an injectable ceramic bone graft substitute that remodels to host bone; CERAMENT G, an injectable ceramic bone graft substitute that remodels to host bone and elutes Gentamicin during the critical first 30 days of bone healing, as well as treats and prevents bone infection; CERAMENT V, an injectable ceramic bone graft substitute that remodels to host bone and elutes Vancomycin during the critical first 30 days of bone healing, as well as treats and prevents bone infection. It also offers CERAMENT Bead Tray, an adjunctive local delivery option for surgeons for targeted delivery to osseous defects and for dead space management. In addition, the company develops preclinical product candidates to promote bone regrowth focusing on trauma, revision arthroplasty, chronic osteomyelitis, and foot and ankle surgery. The company was founded in 1999 and is headquartered in Lund, Sweden.
Home Page: www.bonesupport.com
Scheelevägen 19
Lund,
223 70
Sweden
Phone:
46 4 62 86 53 70
Officers
| Name | Title |
|---|---|
| Mr. Emil Billbäck | Chief Executive Officer |
| Mr. Håkan Johansson | Chief Financial Officer |
| Mr. Michael Wrang Mortensen | Executive Vice President of Global R&D and Operations |
| Ms. Annelie Aava Vikner | Executive Vice President of Global Marketing |
| Ms. Helena L. Brandt | Executive Vice President of Human Resources |
| Dr. Michael Diefenbeck M.D., Ph.D. | Executive VP of Medical & Clinical Affairs and Chief Medical Officer |
| Mr. Fergus MacLeod | GM & Executive VP of Commercial Operations of EUROW |
| Mr. Michael Roth | GM & Executive VP of Commercial Operations of North America |
| Ms. Anna Stegmark | Executive Vice President of Quality Management & Regulatory Affairs |
Exchange: ST
Country: SE : Sweden
Currency: Swedish krone (kr)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 264.1177 |
| Price-to-Book MRQ: | 35.7458 |
| Price-to-Sales TTM: | 29.0458 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 131 |